Journal: International Journal of Molecular Medicine

Article Title: Novel Hsp90 inhibitor JD-02 inhibits HSV-1 infection via the Raf/MEK/ERK signaling pathway

doi: 10.3892/ijmm.2026.5810

Figure Lengend Snippet: JD-02 inhibits HSV-1 replication by suppressing the Raf/MEK/ERK signaling pathway. (A) Western blot analysis was conducted to assess the effects of HSV-1 (MOI=0.1) infection on the protein levels of BRAF, MEK and ERK, with and without treatment using JD-02. (B) Treatment with JD-02 at the specified concentration influences the protein levels of BRAF, MEK and ERK in HaCaT cells over a 12-h period. (C and D) HaCaT cells were subjected to transfection with either N.C. siRNA or ERK siRNA for a period of 48 h. Subsequently, the cells were infected with HSV-1 (MOI=0.1) for an additional 24 h. The DNA copy number of the viral gene UL54, as well as the viral protein expression of gB, ICP0, ICP27, ERK and p-ERK were evaluated. (E) The DNA copy numbers of the viral genes UL30 , UL52 and UL54 in HaCaT cells infected with HSV-1 (MOI=0.1) and subsequently treated with either JD-02 (1 μ M) or U0126 (10 μ M) for 24 h, were quantified using reverse transcription-quantitative PCR. (F) Western blot analysis of viral proteins (gB, ICP0 and ICP27), ERK and p-ERK expression in HaCaT cell infected with HSV-1 (MOI=0.1) and treated with U0126 for indicated concentration. (G) Western blot analysis of UL30 overexpression in HaCaT cells treated with U0126. Data are presented as the mean ± SD (n=3). * P<0.05, ** P<0.01, *** P<0.01 and **** P<0.0001 compared with the HSV-1 group. HSV, Herpes Simplex Virus; MOI, multiplicity of infection; N.C., negative control; siRNA, small interfering RNA; p-, phosphorylated.

Article Snippet: These primary antibodies included ICP0 (1:1,000; cat. no. ab6513; Abcam), ICP27 (1:1,000; cat. no. ab53480; Abcam), gD (1:1,000; cat. no. ab6507; Abcam), gB (1:500; cat. no. sc-56987; Santa Cruz Biotechnology, Inc.), Raf-B (1:500; cat. no. sc-166; Santa Cruz Biotechnology, Inc.), p-BRAF (1:1,000; cat. no. 2696T; Cell Signaling Technology, Inc.), ERK (1:1,000; cat. no. 4695S; Cell Signaling Technology, Inc.), p-ERK (1:1,000; cat. no. 4370S; Cell Signaling Technology, Inc.), MEK1/2 (1:1,000; cat. no. AF6385; Affinity Biosciences), p-MEK1/2 (1:1,000; cat. no. 9154T; Cell Signaling Technology, Inc.), Flag (1:1,000; cat. no. 14793S; Cell Signaling Technology, Inc.), HA (1:1,000; cat. no. 3724S; Cell Signaling Technology, Inc.).

Techniques: Western Blot, Infection, Concentration Assay, Transfection, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Over Expression, Virus, Negative Control, Small Interfering RNA

Journal: iScience

Article Title: RIPOR2 promotes multinucleation of melanoma cells downstream of the RAS/ERK oncogenic pathway

doi: 10.1016/j.isci.2026.115734

Figure Lengend Snippet: RIPOR2 is expressed in the melanocytes of an intermediate-grade melanocytic lesion Adjacent sections of an early BRAF V600E -positive intraepidermal melanoma. Dotted boxes are magnified in the adjacent images. (A) H&E stain shows tissue disorganization in the center of the section. (B) Immunohistochemistry with an anti-BRAF V600E antibody stains the mutated melanocytes and highlights the malignant lesion zone. (C) Immunofluorescence with antiSOX10. (D) Anti-RIPOR2 antibodies demonstrated that RIPOR2 is expressed in SOX10+ epidermal nests of BRAF V600E -positive melanocytes, suggesting that it is expressed in malignant melanocytes. The RIPOR2 staining is cytoplasmic. Blue corresponds to Hoechst nuclear staining in all panels. Scale bars, 100 μm.

Article Snippet: 3.5 μm thick paraffine sections were done from samples and staining was done on a Benchmark ULTRA immunohistochemistry automated system (Ventana, Roche Diagnostics), using the anti-BRAF antibody directed against the V600E mutant form (clone VE1, Eurobio Scientific), dilution 1:250, Optiview DAB detection (Ventana).

Techniques: Staining, Immunohistochemistry, Immunofluorescence